Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)

Background

 PH is the standard of care for previously untreated HER2-positive metastatic BC (MBC) and high-risk HER2-positive early BC (EBC).^{1–3}

- PH can be administered either as two sequential IV administrations⁴ or as a PH FDC SC.⁵
- PH IV and PH FDC SC are usually given with chemotherapy, all of which can trigger anaphylaxis/hypersensitivity that may be life-threatening.^{4,5} Hypersensitivity and administration-related reactions may include dizziness, nausea, chills, fever, vomiting, diarrhoea, uritoraira, angio-oedema, breathing problems or chest pain.⁵
- In the US, PH FDC SC can be administered by healthcare professionals in patients' homes.⁶ Therefore, there is a need to provide a broader characterisation of the incidence and severity of anaphylaxis/hypersensitivity with PH-based regimens.

Methods

- This exploratory analysis was designed to assess the occurrence, incidence and severity of anaphylaxis/hypersensitivity events with PH IV or PH FDC SC in pivotal Roche clinical trials. A time-trend analysis (by cycle) was performed for these studies, excluding those with neoadjuvant use only of PH IV.
- A cumulative search for anaphylaxis/hypersensitivity events (Roche Standard Adverse Event Group Terms and Medical Dictionary for Regulatory Activities v22.1; see preferred terms in supplement) from 11 September 2001 to 25 August 2020 was conducted for patients treated with PH Vor PH FDC SC across all pivotal trials assessed by the European Medicines Agency to support the current PI Van PH FDC SC labels.
- Trials included in this analysis were MBC: CLEOPATRA,⁷ MetaPHER;⁸ EBC: APHINITY,⁹ NeoSphere,¹⁰ TRYPHAENA,¹¹ BERENICE,¹² FeDeriCa,¹³ PHranceSCa¹⁴ (see Table).
- Patients received PH IV or PH FDC SC according to protocol guidance (see supplementary material).

Results

- This analysis includes 4772 patients.^{7–14}
- Incidence of grade ≥3 anaphylaxis/hypersensitivity events was generally low (0.2–2.0% for MBC studies, 0–0.8% in the adjuvant EBC setting and 0–2.8% in the neoadjuvant EBC setting) (Table).
- Anaphylaxis/hypersensitivity events were managed by modifying or discontinuing either chemotherapy, anti-HER2 treatment or both; no fatal events due to anaphylaxis/hypersensitivity were reported.
- Time–trend analyses showed that most all-grade and grade ≥3 anaphylaxis/hypersensitivity events occurred during the first 6–8 cycles of treatment, when PH was administered in combination with chemotherapy (Figures).
- Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally 51% except for one arm in TRYPHAENA, which was 3%); no discontinuations of PH FDC SC had been recorded up until 25 August 2020.

			Patients with events, n (%)		PH discontinuation rate due to anaphylaxis/
		Patients, n	All grades	Grade ≥3	patients, n (%)
PHIV (MBC)	CLEOPATRA (NCT00567190) Placebo + H + D PH IV + D	397 407	36 (9.1) 44 (10.8)	10 (2.5) 8 (2.0)	n/a 4 (1.0)
	MetaPHER (NCT02402712) H SC + P IV + D	412	14 (3.4)	1 (0.2)	1 (0.2)
PH IV (EBC)	APHINITY (NCT01358877) PH IV + chemo Placebo + H IV + chemo	2364 2405	116 (4.9) 86 (3.6)	18 (0.8) 17 (0.7)	6 (0.3) n/a
	NeoSphere ^{1,±} (NCT00545688) Arm A (H IV + D) Arm B (PH IV + D) Arm C (PH IV) Arm D (P IV + D)	107 107 108 94	2 (1.9) 6 (5.6) 6 (5.6) 6 (6.4)	0 1 (0.9) 2 (1.9) 0	n/a 1 (0.9) 1 (0.9) 0
	$\begin{array}{l} \textbf{TRYPHAENA}^{\dagger \pm} \mbox{ (NCT00976989)} \\ Arm \mbox{ (FEC + PH IV \rightarrow PH IV + D)} \\ Arm \mbox{ B (FEC - PH IV + D)} \\ Arm \mbox{ C (PH IV + C + D)} \end{array}$	72 75 76	7 (9.7) 1 (1.3) 10 (13.2)	2 (2.8) 0 2 (2.6)	1 (1.4) 0 2 (2.6)
	BERENICE ^{†,§} (NCT02132949) Cohort A (ddAC + PH IV + pac) Cohort B (FEC + PH IV + D)	199 198	7 (3.5) 5 (2.5)	0 2 (1.0)	0 2 (1.0)
PH FDC SC (EBC)	FeDeriCa (NCT03493854) PH IV + chemo PH FDC SC + chemo	252 248	4 (1.6) 4 (1.6)	1 (0.4)	1 (0.4) 0
	PHranceSCa (NCT03674112) PH IV → PH FDC SC crossover PH FDC SC → PH IV crossover PH IV continuation PH FDC SC continuation	80 80 21** 137**	0 3 (1.9) ¹ 0 2 (1.5)	0 0 0 0	0 0 0 0

Table. Incidence and severity of anaphylaxis/hypersensitivity events in pivotal Roche trials of

The control arms (whood, PH IV or PH FDC SC) are included for comparison. Median number of cycles of P V or PH FDC SC in each study, CLEOPATRA, 242, Mean/FER, 215, SHNINTY, ED, Nossybere, AD, in each arms, TYPHAENA, 60, 30 and 6 to for xma A, Bard C, respectively, BERNECE, 17 0 in each arms, TYPHAENA, 60, 30 and 6 to for xma A, Bard C, respectively, BERNECE, 17 0 in each arms, TVPHAENA, 60, 30 adjuvant; PH renors.25, and 15 adjuvant; FeDerica, 18 0 in each arms, TVPHAENA, 60, 30 adjuvant; PH renors.25, CE : Events reported for the neoadjuvant and 14 0 adjuvant; PH renors.25, CE : Events reported for the neoadjuvant and PH FDC SC. Teacons neoadjuvant and 14 No adjuvant; PH renors.25, CE : Events reported for the neoadjuvant period only. ¹ In NosSphere and TRYPHAENA, PH IV was administered during neoadjuvant treatment. After surgery, patients received adjuvant H orly, ¹ In the SERNECE in to concurning mediation (InS) were recorrected and Chort A (in = 181) and one event (ISS) in Chort B (in = 190). ¹ Grade as a surger as an allergic reaction to concurning mediation (Instead) in the SERNECE (INS) and the event of the surgery of the surgery adjuvant treatment. After surgery, batterist received adjuvant H orly, ¹ In the SERNECE (INS) and the event of the surgery of the surgery adjuvant treatment and the surgery calculated to the INS). ¹ Grade as a surgery calculated to the INS of the surgery of the surg

References

P

 Cardoso F, et al. Ann Oncol. 2019;30:1194–1220; 2. Cardoso F, et al. Ann Oncol. 2020;31:1623–1649; 3NCCN Breast Cancer Guidelines. Version 4, 2021;
 4: FDA perturnab prescribing information. Available at: https://www.gene.com/download/df/bergita_prescribing.pdf. Accessed August 2021;
 5: FDA PH FDC SC prescribing information. Available at: https://www.accessdata. fda.gov/drugsat/da_docs/label/2020/761170s000lbi.pdf. Accessed August 2021;


6. PH FDC SC FDA approval 2020. Available at: https://www.fda.gov/newsevents/press-amouncement/fdat_approves-breast-cance-treatment-can-beadministered-home-health-care-professional. Accessed August 2021; 7. Baselga J, et al. N Engl Med 2012; 366:109–119. 8. Kummer S, et al. Breast Cancer Res Treat. 2021;187:467–476; 9. von Minckvitz G, et al. N Engl J Med. 2017;377:122-31; 10. Gianni, L et al. Lancel Oncol 2012;1325-32;

 Schneeweiss A, et al. Ann Oncol. 2013;24:2278-84; 12. Swain SM, et al. Ann Oncol. 2018;29:646-53; 13. Tan AR, et al. Lancet Oncol. 2021;22:85-97; 14. O'Shaughnessy J, et al. Eur J Cancer 2021;152:223–232.

Conflicts of interest

SMS reports honoraria received for consulting or advisory role from AstraZeneca, Daichi Sankyo, F. Hoffmann-La Roche Ldu'Genentech, Inc., Exact Sciences (Genomic Health), Molecular Tempiates, Silverback Therapeutics, Merck, Lilly, Natera, Athenex and Beijing Medical Foundation; advisory board for Inviatr, research grants or funding to institution received from F. Hoffmann-La Roche LudGenettech, Inc. and Kalos Genetics, travel/accommodation/expenses from F. Hoffmann-La Roche LudGenettech, Inc., Daickl Smilyou for third-party writing assistance for this ePoster from F. Hoffmann-La Roche LudGenes refer to the abstract for all author conflicts of interest. This study was sponsored by F. Hoffmann-La Roche Lud.

Figures. Incidence of anaphytaxis/hypersensitivity events during HER2-targeted therapy by cycle.* (a) Events in CLEOPATRA; b) events in MetaPHER; (c) events in APHINITY; (d) events in BERENICE; (e) events in FeDeriCa



Conclusions

PH IV and PH FDC SC are well tolerated, with few grade ≥3 anaphylaxis/hypersensitivity events reported with PH IV
and no grade ≥3 events with PH FDC SC.

 The majority of the anaphylaxis/hypersensitivity events were grade 1/2 and occurred within the first 6–8 cycles when PH IV or PH FDC SC were given in combination with chemotherapy.

Patients should be closely monitored during and after PH IV infusions and PH FDC SC injections. If a significant
infusion- or injection-related reaction occurs, slow down or pause treatment and administer appropriate medical
therapies. Patients should be carefully monitored until complete resolution of symptoms. Permanently discontinue
PH IV or PH FDC SC in patients who experience anaphylaxis or severe infusion- or injection-related reactions.⁴

Acknowledgements

We would like to thank the patients, their families, the nurses and the investigators who participated in these studies. Support for third-party writing assistance for this poster, furnished by Alison McGonagle, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd.



Copies of this ePoster obtained through QR (Quick Response) code are for personal use only and may not be reproduced without written permission of the authors.

Please contact the lead author at sms248@georgetown.edu for permission to reprint and/or distribute. Presented at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress, 16–21 September.